Literature DB >> 27133142

Neuropathy in the DCCT/EDIC-What Was Done Then and What We Would Do Better Now.

R Pop-Busui1, C Martin2.   

Abstract

The Diabetes Control and Complications Trial (DCCT) and its epidemiological follow-up, the Epidemiology of Diabetes Interventions and Complications (EDIC) provide important insight on the natural history of distal symmetrical polyneuropathy and cardiovascular autonomic neuropathy in patients with type 1 diabetes and on the impact of intensive treatment of hyperglycemia on disease progression. This chapter summarizes the design and methods used for neuropathy evaluations both in the DCCT and in EDIC, the characteristics of the DCCT/EDIC patient population, and summarizes the findings of the DCCT/EDIC relative to neuropathic complications of type 1 diabetes. Lessons learned from the DCCT and EDIC experiences of longitudinal assessments of neuropathic complications are also reviewed.
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autonomic neuropathy; Diabetes Control and Complications Trial; Distal symmetrical polyneuropathy; Epidemiology of Diabetes Interventions and Complications; Natural history

Mesh:

Year:  2016        PMID: 27133142     DOI: 10.1016/bs.irn.2016.02.020

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  8 in total

1.  A novel curcumin derivative for the treatment of diabetic neuropathy.

Authors:  Daniel J Daugherty; Alexandra Marquez; Nigel A Calcutt; David Schubert
Journal:  Neuropharmacology       Date:  2017-11-06       Impact factor: 5.250

2.  Amelioration of Both Central and Peripheral Neuropathy in Mouse Models of Type 1 and Type 2 Diabetes by the Neurogenic Molecule NSI-189.

Authors:  Corinne G Jolivalt; Alexandra Marquez; David Quach; Michelle C Navarro Diaz; Carlos Anaya; Betelhem Kifle; Nabeel Muttalib; Gabriela Sanchez; Lucy Guernsey; Mike Hefferan; Darrel R Smith; Paul Fernyhough; Karl Johe; Nigel A Calcutt
Journal:  Diabetes       Date:  2019-09-06       Impact factor: 9.461

3.  Deletion of the insulin receptor in sensory neurons increases pancreatic insulin levels.

Authors:  Caleb W Grote; Natalie M Wilson; Natalie K Katz; Brianne L Guilford; Janelle M Ryals; Lesya Novikova; Lisa Stehno-Bittel; Douglas E Wright
Journal:  Exp Neurol       Date:  2018-04-09       Impact factor: 5.330

4.  Evaluation of the neonatal streptozotocin model of diabetes in rats: Evidence for a model of neuropathic pain.

Authors:  Paulino Barragán-Iglesias; Víctor Hugo Oidor-Chan; Emanuel Loeza-Alcocer; Jorge Baruch Pineda-Farias; Isabel Velazquez-Lagunas; Ana Belen Salinas-Abarca; Enrique Hong; Alicia Sánchez-Mendoza; Rodolfo Delgado-Lezama; Theodore J Price; Vinicio Granados-Soto
Journal:  Pharmacol Rep       Date:  2017-09-14       Impact factor: 3.024

Review 5.  Lost in Translation? Measuring Diabetic Neuropathy in Humans and Animals.

Authors:  Heung Yong Jin; Seong-Su Moon; Nigel A Calcutt
Journal:  Diabetes Metab J       Date:  2020-12-15       Impact factor: 5.376

6.  Serum Levels of Inflammatory Proteins Are Associated With Peripheral Neuropathy in a Cross-Sectional Type-1 Diabetes Cohort.

Authors:  Sharad Purohit; Paul Minh Huy Tran; Lynn Kim Hoang Tran; Khaled Bin Satter; Mingfang He; Wenbo Zhi; Shan Bai; Diane Hopkins; Melissa Gardiner; Chandramohan Wakade; Jennifer Bryant; Risa Bernard; John Morgan; Bruce Bode; John Chip Reed; Jin-Xiong She
Journal:  Front Immunol       Date:  2021-03-31       Impact factor: 7.561

7.  CEBPβ regulation of endogenous IGF-1 in adult sensory neurons can be mobilized to overcome diabetes-induced deficits in bioenergetics and axonal outgrowth.

Authors:  Mohamad-Reza Aghanoori; Prasoon Agarwal; Evan Gauvin; Raghu S Nagalingam; Raiza Bonomo; Vinith Yathindranath; Darrell R Smith; Yan Hai; Samantha Lee; Corinne G Jolivalt; Nigel A Calcutt; Meaghan J Jones; Michael P Czubryt; Donald W Miller; Vernon W Dolinsky; Virginie Mansuy-Aubert; Paul Fernyhough
Journal:  Cell Mol Life Sci       Date:  2022-03-17       Impact factor: 9.207

8.  Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system.

Authors:  Sarah Demaré; Asha Kothari; Nigel A Calcutt; Paul Fernyhough
Journal:  Expert Rev Neurother       Date:  2020-12-04       Impact factor: 4.287

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.